Aptorum Group Announces Pricing of $9.0 Million Public Offering

Aptorum Group Limited (Nasdaq:APM, Euronext Paris:APM) (“Aptorum Group” or “Aptorum”), a biopharmaceutical company focused on novel technologies including the targeting of infectious diseases,
today announced the pricing of a public offering of 2,769,231 Aptorum’s Class A ordinary shares (or ordinary share equivalents) and warrants to purchase up to 2,769,231 Class